olivLaw · US equity research
Impact BioMedical Inc. IBO
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Impact BioMedical develops and patents scientific technologies that it licenses or co-develops with health and wellness partners, including medicines for neurological, oncologic and inflammatory diseases. The company has very small revenue, almost entirely from sales of its Celios air purifiers, and 2026 filings show a slowdown worth watching as it pursues a planned merger.
At the close of 04 Nov 2026, Impact BioMedical Inc. (IBO) stock was 4.10 USD (+1.99% on the day), with market capitalisation 442.1 m USD, P/E 560.3 on diluted EPS of -0.38 USD over the last 12 months, beta -0.67, 52-week range 2.68–9.87 USD. Latest reported quarter (Q2 2026): revenue of 3.0 k USD (−57.1% YoY), net income of -699.0 k USD, diluted EPS -0.01 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 48.1
- neutral
- Bollinger (20, 2)
- 2.91 – 4.53
- in the upper half of the band · %B 0.73 · band width 43.6%
- SMA 50 / 200
- 5.06 / 6.23
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.29 / -0.43
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −15.3% | −1.1% | −14.2 pp | — |
| 3 months | −24.7% | −0.5% | −24.2 pp | — |
| 6 months | −49.0% | +4.4% | −53.4 pp | — |
| Year to date | −35.9% | +12.3% | −48.2 pp | — |
| 1 year | −39.2% | +13.5% | −52.8 pp | +8.9% |
| 3 years | unavailable | +76.4% | unavailable | +13.0% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 7.0 k | 18.0 k | 7.0 k | 7.0 k | 3.0 k |
| Cost of revenue | — | — | — | 1.0 k | 1.0 k | 422.0 k | — | 1.0 k |
| Research & development | 82.0 k | -108.0 k | 103.0 k | 75.0 k | 52.0 k | 110.0 k | 46.0 k | 76.0 k |
| SG&A | 132.0 k | 294.0 k | 248.0 k | 246.0 k | 261.0 k | 118.0 k | 1.6 m | 167.0 k |
| Operating income | -1.1 m | -26.2 m | -1.0 m | -1.2 m | -948.0 k | -1.2 m | -2.3 m | -702.0 k |
| Depreciation & amortisation | 281.0 k | 279.0 k | 283.0 k | 288.0 k | 288.0 k | 286.0 k | 285.0 k | 284.0 k |
| Interest expense | 305.0 k | 270.0 k | 271.0 k | 260.0 k | 262.0 k | 0 | — | — |
| Pre-tax income | 4.2 m | -27.1 m | -1.3 m | -14.4 m | -1.5 m | 2.7 m | -2.3 m | -700.0 k |
| Net income | 4.2 m | -27.1 m | -1.3 m | -14.3 m | -1.5 m | 5.2 m | -2.3 m | -699.0 k |
| Diluted EPS | 0.06 | — | -0.11 | -1.18 | -0.12 | — | -0.02 | -0.01 |
| Operating cash flow | -1.0 m ≈ | -986.0 k | -682.0 k | -694.0 k ≈ | -613.0 k ≈ | 99.0 k | -464.0 k | 470.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 50.0 k | unavailable | unavailable | 32.0 k |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable |
| Net income | -7.3 m | -4.3 m | -24.7 m | -11.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.10 | -0.07 | -2.30 | -0.38 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable |
| net % | -14,510.0% | unavailable | unavailable | -36,993.8% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 3.0 k USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 15.6 m USD
- Total assets
- 17.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.35x
- ROE
- -103.9%
- ROA
- -62.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 50.0 k | — | — | 32.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Cost of revenue | — | — | — | 424.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Gross profit | — | — | — | -392.0 k ≈ | SEC (XBRL)· 11 Mar 2026derived |
| Research & development | 1.2 m | 1.7 m | 278.0 k | 340.0 k | SEC (XBRL)· 11 Mar 2026verified |
| SG&A | 325.0 k | 315.0 k | 718.0 k | 873.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Operating income | -3.4 m | -4.0 m | -28.8 m | -4.3 m | SEC (XBRL)· 11 Mar 2026verified |
| Depreciation & amortisation | 1.1 m | 1.1 m | 1.1 m | 1.1 m | SEC (XBRL)· 11 Mar 2026verified |
| EBITDA | -2.3 m ≈ | -2.9 m ≈ | -27.6 m ≈ | -3.1 m ≈ | SEC (XBRL)· 11 Mar 2026derived |
| Interest expense | 462.0 k | 444.0 k | 1.1 m | 793.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Pre-tax income | -7.9 m | -4.4 m | -24.7 m | -14.5 m | SEC (XBRL)· 11 Mar 2026verified |
| Income tax | -621.0 k | — | 33.0 k | -2.6 m | SEC (XBRL)· 11 Mar 2026verified |
| Net income | -7.3 m | -4.3 m | -24.7 m | -11.8 m | SEC (XBRL)· 11 Mar 2026verified |
| Diluted EPS | -0.10 | -0.07 | -2.30 | -0.38 | SEC (XBRL)· 11 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 2.0 k | 1.0 k | 2.0 m | 3.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Receivables | — | 0 | — | 5.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Inventories | — | — | — | 63.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Current assets | 122.0 k | 332.0 k | 2.4 m | 411.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Property, plant & equipment, net | 276.0 k | 287.0 k | 17.0 k | — | SEC (XBRL)· 28 Mar 2025verified |
| Goodwill | 25.1 m | 25.1 m | 25.1 m | — | SEC (XBRL)· 14 May 2025verified |
| Intangibles (excl. goodwill) | 20.0 m | 18.9 m | 17.8 m | 17.0 m | SEC (XBRL)· 11 Mar 2026verified |
| Total assets | 46.5 m | 44.6 m | 20.3 m | 17.4 m | SEC (XBRL)· 11 Mar 2026verified |
| Accounts payable | 539.0 k | 832.0 k | 314.0 k | 347.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Current liabilities | 10.6 m | 13.1 m | 9.8 m | 1.2 m | SEC (XBRL)· 11 Mar 2026verified |
| Total liabilities | 13.8 m | 16.4 m | 13.1 m | 1.9 m | SEC (XBRL)· 11 Mar 2026verified |
| Equity | 32.7 m | 28.3 m | 7.2 m | 15.6 m | SEC (XBRL)· 11 Mar 2026verified |
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | -2.2 m | -2.9 m | -2.9 m | -1.9 m | SEC (XBRL)· 11 Mar 2026verified |
| Investing cash flow | -349.0 k | -15.0 k | 2.0 k | 3.0 k | SEC (XBRL)· 11 Mar 2026verified |
| Financing cash flow | 2.5 m | 2.9 m | 4.9 m | -109.0 k | SEC (XBRL)· 11 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 35.4% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 442.1 m USD
Key indicators
Coverage and freshness
Score by group
35% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.11 – 0.32 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E0.11 – 0.32 (Mid 0.16)16 companies used · median multiple 22.1x · quartiles 14.6x – 43.2xABBV, ABT, ALNY, BMY, COLL, HRMY, JNJ, KMDA, LLY, OMER, PFE, REGN, RPRX, UTHR, VRTX, ZTS
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 2,254.3% | 100 (vs peers) | 18% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -13.8% | 0 (on a fixed band) | 24% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -6.4x | 0 (on a fixed band) | 18% |
| Current ratio · Balance sheet | 0.2x | 0 (on a fixed band) | 12% |
| P/E (TTM) · Valuation | 560.3x | 5 (vs peers) | 29% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial100/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial5/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Impact BioMedical, INC. (IBO). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 32.0 k USD in 2025; net margin 2,254.3%; ROE 371.3%.
The estimated value range is 0.11–0.32 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 0.16 USD, the price of 4.10 USD leaves a potential of -96.1% (value / price − 1) and a margin of safety of -2,437.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 2,254.3%
What contradicts it
- Revenue CAGR 3Y: -13.8%
- Interest coverage: -6.4x
- Current ratio: 0.2x
- P/E (TTM): 560.3x
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| HRMYHarmony Biosciences Holdings, Inc. | 2.0 bn | 11.4 | 18.7% | 18.1% | +21.5% | −2% / +18% |
| OMEROmeros Corp | 1.3 bn | 10.5 | — | — | −34.0% | +88% / +730% |
| VSTMVerastem, Inc. | 892.0 m | — | -471.2% | -231.6% | +209.1% | −7% / +43% |
| COLLCollegium Pharmaceutical, Inc. | 770.6 m | 19.1 | 17.6% | 5.9% | +23.6% | −49% / −8% |
| IBOImpact BioMedical, INC. | 442.1 m | 560.3 | 371.3% | 2,254.3% | unavailable | −39% / unavailable |
| KMDAKamada Ltd | 428.0 m | 21.2 | 7.6% | 11.2% | +12.1% | +11% / +57% |
| EPRXEupraxia Pharmaceuticals Inc. | 240.9 m | — | -66.8% | — | unavailable | +9% / unavailable |
1- and 3-year price returns: for IBO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 2.19 Total return -47% · Per year -47% | 3.90 Total return -5% · Per year -5% | 5.89 Total return 44% · Per year 44% |
| 3 years | 1.74 Total return -58% · Per year -25% | 3.52 Total return -14% · Per year -5% | 5.89 Total return 44% · Per year 13% |
| 5 years | 1.38 Total return -66% · Per year -20% | 3.17 Total return -23% · Per year -5% | 5.89 Total return 44% · Per year 8% |
- Exit P/E± 0.88
- Net margin± 0.62
- Annual revenue growth± 0.56
- Annual dilution± 0.05
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Impact BioMedical develops and patents scientific technologies that it licenses or co-develops with health and wellness partners, including medicines for neurological, oncologic and inflammatory diseases. The company has very small revenue, almost entirely from sales of its Celios air purifiers, and 2026 filings show a slowdown worth watching as it pursues a planned merger.1
SWOT
Strengths
- Extensive portfolio of issued and pending patents that supports the value of licensed technologies.
- Active licensing agreement with a pharmaceutical partner that could generate milestone and royalty payments.
- Major debt settled through conversion, simplifying the balance sheet and removing non-trade debt obligations.
Weaknesses
- Very small revenue and near-total dependence on a single product line, Celios.
- Recurring operating losses and an uncertain timeline to profitability.
- Very small workforce and reliance on shared services with another shareholder.
Opportunities
- If a licensing partner brings products to market, the company could receive milestone and royalty payments.
- Interest in air purification could support expansion of the Celios line.
- Completing the planned merger could bring capital and manufacturing resources.
Threats
- Sales difficulties and impaired inventory could continue to weigh on Celios revenue.
- Larger competitors may have superior resources and could develop similar technologies faster.
- Changes in patent law could raise costs and reduce licensing revenue.
Risks
- Protection of intellectual propertyhigh
If patents are not adequately protected or are challenged, the company could lose potential revenue and suffer operational harm. 1
- Need for fundinghigh
The company states it may not obtain the funds its business plan requires, which could materially affect its financial condition. 1
- Dependence on partnersmedium
The loss of a partner or its failure to perform could delay development and commercialization of products. 1
- Clinical trial outcomesmedium
Clinical trials may fail or reveal side effects, which could reduce the value of products for partners. 1
- Cybersecuritylow
Breaches of the company's or third-party vendors' systems could expose sensitive data and interrupt operations. 1
Investment thesis
What would need to be true (bull case)
- The patent portfolio and licensing agreements could generate significant revenue if partners bring products to market.
- Elimination of major debt and the planned merger could strengthen the balance sheet and accelerate new product development.
- The Celios line could become a steadier revenue source if demand for air purification keeps growing.
What would break the thesis
- Revenue is nearly nonexistent and operating losses could continue without a clear timeline to profitability.
- Celios sales declined in the second quarter of 2026, and impaired inventory suggests sales difficulties.
- The company depends on partners and outside funding; if these do not materialize, plans could be delayed.
What to watch
- Status of the merger with Dr. Ashleys Limited and the structure of the new entity2026
- Celios revenue and inventory trendsQ3 2026
- Payments from ProPhase Laboratories under the Linebacker and Equivir licensesnext 10-K
- Need for additional funding and how it is coverednext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms and patents unique scientific technologies that can be developed into new health and wellness offerings, in collaboration with external partners through licensing, co-development or joint ventures. Its operations run through four principal subsidiaries, and its business model includes partnering and potentially direct sales. 1 Reported revenue is minimal: in fiscal 2025 the company recorded 32000 USD from retail sales of the Celios technology, acquired in February 2025. 1
The company manages an intellectual property portfolio that it describes as central to its value: at the end of 2025 it had sixty issued and over sixty pending patents, and its annual report states it holds rights to sixty-nine issued patents. 1 Management presents this portfolio as the core asset, although it has not yet generated significant revenue from it. 1
Impact BioMedical was incorporated in Nevada in 2018 and has a very small workforce: two full-time employees and six employees shared with DSS as of December 31, 2025. 1 The company has announced a reverse merger with Dr. Ashleys Limited and a debt conversion with DSS, Inc. that settled about 15 million USD of debt, which could change its financial structure. 1
Segments
Licensed and developing technologies
The Linebacker and Equivir platforms are licensed to ProPhase Laboratories (NASDAQ: PRPH), from which Impact could receive milestone and royalty payments. Laetose, with a composition patent allowed in the United States, targets consumer or biopharmaceutical products, while 3F, developed with Chemia Corporation, targets antimicrobial and industrial additive uses. 1
Celios air purification
Celios is the only product line generating sales in the periods reviewed. Acquired in 2025, the technology uses a three-stage mechanical filtration system that the company says could generate immediate revenue. Sales run through online channels and third-party distributors; revenue in the first six months of 2026 rose versus the same period of 2025, but the second quarter declined. 12
Operating costs
Total costs fell to 705000 USD in the second quarter of 2026 from 1160000 USD a year earlier, while for the first six months total costs rose to 3000000 USD, influenced by a large stock-based compensation charge. 2
Market context
The company operates in antivirals, antimicrobials, specialty biopharmaceuticals and consumer wellness products, often derived from natural elements. It targets both developed and emerging markets and argues its solutions address unmet medical needs. 1
Revenue depends mainly on licensing, milestone payments and royalties from pharmaceutical and consumer-goods partners, while direct sales remain limited. If partners fail to commercialize the technologies, revenue could remain small. 1
Trends
- Interest in indoor air qualitytailwind
Demand for air purifiers with advanced filtration could rise after concerns about airborne disease, which would support the Celios line. The company names tuberculosis and influenza among its target areas. 1
- Pressure on purifier revenueheadwind
Celios sales declined in the second quarter of 2026, and storage costs and impaired inventory point to sales difficulties. If the decline continues, the effect on revenue could become visible. 21
- Consolidation in biotechnologymixed
Mergers and acquisitions in pharmaceuticals could concentrate resources among a few large players, which could intensify competition for smaller companies. Impact relies on partnerships to offset this disadvantage. 1
- Patent regulationheadwind
Legislative changes on obtaining and enforcing patents, including at the United States Patent and Trademark Office, could raise litigation costs and reduce licensing revenue. 1
Competitive position
Impact BioMedical competes with major pharmaceutical companies, specialty pharmaceutical and biotechnology firms, academic institutions, governmental agencies and public and private research institutes. The company says many competitors have substantially greater financial, technical and human resources. 1
Its stated advantages are its technology, development experience, scientific knowledge and patent portfolio. Success could nevertheless depend on attracting qualified personnel, obtaining regulatory approvals and negotiating competitive pricing and reimbursement. 1
- ProPhase LaboratoriesPRPH
Partner that holds licenses for Linebacker and Equivir with worldwide development and commercialization rights.
- Chemia Corporation
Development partner for the 3F technology, a developer and manufacturer of fragrances and flavors.
- Major pharmaceutical companies
Competitors with far greater resources that could develop or license similar compounds.
- Biotechnology companies and research institutes
Competitors that could accelerate discovery of novel compounds and affect the success of products.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report03 Nov 2026Regulation FD disclosure · Financial statements and exhibits
- Current report09 Oct 2026Amendments to articles or bylaws · Financial statements and exhibits
- Current report17 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report15 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report07 Aug 2026
- Quarterly report12 May 2026
- Annual report11 Mar 2026
- Current report04 Mar 2026Material agreement · Financial statements and exhibits
- Quarterly report07 Nov 2025
- Current report06 Nov 2025Shareholder vote
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Impact BioMedical Inc. · 11 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Impact BioMedical Inc. · 07 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.